22.01.2010 • News

Intercell, GSK team up for Patch Vaccines

Britain's Glaxosmithkline said it was teaming up with Austrian vaccine maker Intercell to develop patch vaccines that can be delivered without needles. GSK will make an up-front cash contribution of €33.6 million and an equity investment of up to €84 million via staggered share purchases of up to 5% of the company. The deal will include Intercell's candidate vaccine for travellers' diarrhea, which is currently in final stage clinical trials, and a potential single application pandemic flu vaccine which is in Phase II trials. The firms said they would also be exploring the use of the patch technology for other vaccines in GSK's portfolio.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Top-Feature

most read